| Name | Title | Contact Details |
|---|
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.
Celera Corporation (Celera) is a healthcare business delivering personalized disease management through a combination of products and services. The Company operates in three segments: a clinical laboratory testing service business (Lab Services), a
Stern At Home Therapy is transforming how outpatient therapy is experienced.
EYEVANCE Pharmaceuticals` mission is to develop and commercialize INNOVATIVE and IMPACTFUL ophthalmic products to enable optimal vision and better quality of life for all patients
Lumate Health is a Cognitive Behavioral Teletherapy Platform treating teenagers and young adults with anxiety-related mental health disorders.